Contract Pharma Staff01.19.21
Jianshun Biosciences (JS Bio) recently formed its strategic partnership with Etta Biotech to set up a high titer transient protein expression platform for high quality protein production using JS Bio’s transient transfection media. JS Bio becomes the exclusive cell culture supplier for Etta Biotech’s transient transfection high titer protein expression platform.
Etta Biotech is a leading cell electroporation technology and equipment supplier. Its proprietary large-capacity flow electroporator, X-Porator F1, is one of the only two products of its kind in the world, and leads the market with its outstanding performance and customer value. Etta Biotech's F1 equipment, paired with a completed process optimization protocol, can significantly increase protein expression titer and quality with transient transfection, therefore reducing the user’s operational cost and shortening the R&D cycle. It has become the de facto standard equipment for high titer transient protein expression platforms used by many leading Chinese antibody drug pharmaceutical companies and IVD (In Vitro Diagnostics) companies since its launch in Oct. 2018.
In accordance with the strategic agreement, JS Bio will provide Etta Biotech with customized cell culture media for its transient protein expression platform. The two parties also plan to join force further to build a rapid protein production platform aiming at producing gram-scale protein for R&D, e. g. molecular assessment within two weeks after receiving plasmids, to advance R&D process for antibody drug development. With its sophisticated quality and service systems, JS Bio will accelerate the application of Etta Biotech’s products in antibody drug development in the industry.
“I am so glad to have the opportunity to join hands with the benchmark company in cell culture media, JS Bio,” said Dr. Edward Dai, chairman and chief executive officer, Etta Biotech. “Its cell culture media specially developed for Etta Biotech’s electroporator can further increase our customers’ protein output, and guarantee a supply of reliable cell culture medium products for Etta Biotech’s high titer protein transient expression platform. Etta Biotech, in return, will help JS Bio to expand its media market, and develop electroporation equipment capable for 100L and over transient protein expression systems, that will empower the CDMO service platform of Thousand Oaks Biopharmaceuticals Co., Ltd., JS Bio’s parent company. Making this partnership is a mutually beneficial cooperation.”
Dr. Shun Luo, chairman and president, JS Bio, said, “Presently, we and Etta Biotech have achieved great progresses in developing transient transfection platforms with high protein expression titer, and protein production systems at scale. With its excellent electroporation technology and equipment, Etta Biotech has become a world leader in its field. I feel so honored to work with Etta Biotech, and Dr. Dai. In the future, JS Bio will continue to take advantage of our customized cell culture media development capability and commercial supply capacity, to maximize our mutual benefits for Etta Biotech as well as for Thousand Oaks Biopharma, and together we will make significant contributions to the fast growing biopharmaceutical industry.”
Etta Biotech is a leading cell electroporation technology and equipment supplier. Its proprietary large-capacity flow electroporator, X-Porator F1, is one of the only two products of its kind in the world, and leads the market with its outstanding performance and customer value. Etta Biotech's F1 equipment, paired with a completed process optimization protocol, can significantly increase protein expression titer and quality with transient transfection, therefore reducing the user’s operational cost and shortening the R&D cycle. It has become the de facto standard equipment for high titer transient protein expression platforms used by many leading Chinese antibody drug pharmaceutical companies and IVD (In Vitro Diagnostics) companies since its launch in Oct. 2018.
In accordance with the strategic agreement, JS Bio will provide Etta Biotech with customized cell culture media for its transient protein expression platform. The two parties also plan to join force further to build a rapid protein production platform aiming at producing gram-scale protein for R&D, e. g. molecular assessment within two weeks after receiving plasmids, to advance R&D process for antibody drug development. With its sophisticated quality and service systems, JS Bio will accelerate the application of Etta Biotech’s products in antibody drug development in the industry.
“I am so glad to have the opportunity to join hands with the benchmark company in cell culture media, JS Bio,” said Dr. Edward Dai, chairman and chief executive officer, Etta Biotech. “Its cell culture media specially developed for Etta Biotech’s electroporator can further increase our customers’ protein output, and guarantee a supply of reliable cell culture medium products for Etta Biotech’s high titer protein transient expression platform. Etta Biotech, in return, will help JS Bio to expand its media market, and develop electroporation equipment capable for 100L and over transient protein expression systems, that will empower the CDMO service platform of Thousand Oaks Biopharmaceuticals Co., Ltd., JS Bio’s parent company. Making this partnership is a mutually beneficial cooperation.”
Dr. Shun Luo, chairman and president, JS Bio, said, “Presently, we and Etta Biotech have achieved great progresses in developing transient transfection platforms with high protein expression titer, and protein production systems at scale. With its excellent electroporation technology and equipment, Etta Biotech has become a world leader in its field. I feel so honored to work with Etta Biotech, and Dr. Dai. In the future, JS Bio will continue to take advantage of our customized cell culture media development capability and commercial supply capacity, to maximize our mutual benefits for Etta Biotech as well as for Thousand Oaks Biopharma, and together we will make significant contributions to the fast growing biopharmaceutical industry.”
